Lovastatin induces VSMC differentiation through inhibition of Rheb and mTOR

Robert J Wagner1, Kathleen A Martin, Richard J Powell

  • 1Section of Vascular Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756, USA.

Insights

Lovastatin promotes cardiovascular health by inhibiting Rheb and mTORC1 signaling, leading to vascular smooth muscle cell (VSMC) differentiation. This mechanism enhances the cardioprotective effects of statins beyond cholesterol reduction.

Area of Science:

  • Cardiovascular Biology
  • Molecular Pharmacology
  • Cellular Signaling

Background:

  • Cholesterol-independent effects of statins contribute to cardioprotection, but mechanisms are unclear.
  • Mammalian target of rapamycin complex 1 (mTORC1) inhibition induces vascular smooth muscle cell (VSMC) differentiation.
  • Statins' effects on VSMC phenotype warrant investigation.

Purpose of the Study:

  • To investigate the effects of lovastatin on vascular smooth muscle cell (VSMC) phenotype.
  • To elucidate the role of mammalian target of rapamycin complex 1 (mTORC1) signaling in lovastatin-induced VSMC differentiation.
  • To identify upstream regulators of mTORC1 involved in lovastatin's actions.

Main Methods:

  • Investigated lovastatin's impact on VSMC phenotype and mTORC1 signaling.
  • Utilized Rheb overexpression and knockdown (small interfering RNA) to assess its role in mTORC1 regulation.
  • Examined mTORC1 activity and contractile protein expression in patient-derived cells and an ex vivo angioplasty model.

Main Results:

  • Lovastatin inhibits mTORC1 signaling, which is essential for VSMC differentiation.
  • Lovastatin's mTORC1 inhibition is dependent on farnesylation, implicating the G protein Rheb.
  • Rheb activity inversely correlates with contractile protein expression; Rheb knockdown mimics lovastatin's effects.
  • Elevated mTORC1 activity in intimal hyperplasia lesions was reduced by lovastatin treatment.
  • Lovastatin inhibited mTORC1 and preserved contractile proteins in an ex vivo angioplasty model.

Conclusions:

  • Lovastatin promotes a differentiated VSMC phenotype through Rheb and mTORC1 inhibition.
  • This mechanism contributes to the cardioprotective effects of statins, independent of cholesterol.
  • Targeting Rheb-mTORC1 signaling offers a potential therapeutic strategy for vascular diseases.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...